在接受左心室辅助器械评估的患者中,决策,生活质量和生存率的性别差异
Joseph M Kim1, Muhammad H Maqsood2, Tracy Makuvire3
1Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United States of America.
PloS one
|October 25, 2023
概括
患有心力衰竭的女性在选择左心室辅助器件 (LVAD) 时需要更多的支持. 这项研究发现了决策和结果中的性别差异,强调了需要量身定制的支持.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 健康 结果 研究 研究 结果
背景情况:
- 女性接受左心室辅助器件 (LVAD) 的可能性较低,并且经常经历较差的结果.
- 性别对LVAD决策及其后续影响的影响仍然未得到充分研究.
研究的目的:
- 分析考虑LVAD治疗的患者在决策和结果中的基于性别的差异.
- 在患者体验上评估决策支持干预措施的有效性.
主要方法:
- 阶梯 DECIDE-LVAD 试验的子组分析.
- 进行LVAD评估的男性和女性之间的比较结果和心理社会因素.
主要成果:
- 与男性相比,接受LVAD的女性较少 (61%对70%).
- 男性在干预后的决策冲突和感知压力的显著改善,而女性没有.
- 妇女报告了更高的基线决策遗憾和抑郁症状,有些人在随访时持续存在.
结论:
- 在LVAD植入决策过程中,女性可能需要加强决策支持.
- 强化心理社会支持可能有利于女性导航LVAD治疗.
相关概念视频
Cardiomyopathy V: Interprofessional Care
14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Mitral Stenosis IV: Nursing Management
13
A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
13
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Heart Failure VI: Adjunct Therapies
15
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
Heart Failure V: Medical Management
9
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9
Heart Failure IV: Classification and Diagnostic Evaluation
18
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
18


